RxDoctor Payments Data

Sherie Ramsgard

Psychiatric/Mental Health · Syracuse, NYNPI 1457305534

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,625 of the $52,429 with a category attached, or 81.3%. AbbVie accounts for 89.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $21,597 and has fallen 53.8% since, to $9,973 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,429in general payments, 2019–2025

Across 397 payments — averaging $132.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$47K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$852
  • Teva Pharmaceuticals USA, Inc.$838
  • Lundbeck LLC$720
  • Axsome Therapeutics, Inc.$551
  • Otsuka America Pharmaceutical, Inc.$536
  • plus $2K from 11 others

What the payments were for

  • Speaking & faculty fees$42,62581%
  • Travel & lodging$2,3284%
  • Food & beverage$7,37514%
  • Education$1010%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,429 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$22,325
TrintellixVortioxetine Hydrobromide21$18,402
Bupropion XlBupropion Hcl45$944
Duloxetine Hcl39$867
Alprazolam64$541
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$532
Olanzapine28$477
Sertraline Hcl54$452
Clozapine11$399
Temazepam22$343
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$322
Clonazepam23$198
Lorazepam33$172
Fluoxetine Hcl105$172
Trazodone Hcl25$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$536$22,32514 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$373$18,40221 claims
Almatica Pharma LLCSertraline Hcl$58$45254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →